These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25828967)

  • 1. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience.
    Kissova J; Ovesna P; Bulikova A; Zavřelova J; Penka M
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):448-53. PubMed ID: 25828967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
    Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
    Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
    Duchemin J; Ugo V; Ianotto JC; Lecucq L; Mercier B; Abgrall JF
    Thromb Res; 2010 Sep; 126(3):238-42. PubMed ID: 20656333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
    Taniguchi Y; Tanaka H; Luis EJ; Sakai K; Kumode T; Sano K; Serizawa K; Rai S; Morita Y; Hanamoto H; Tsubaki K; Nishio K; Matsumura I
    Int J Hematol; 2017 Nov; 106(5):691-703. PubMed ID: 28780601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
    Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
    Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Aswad MH; Kissova J; Ovesna P; Rihova L; Penka M
    In Vivo; 2021; 35(6):3345-3353. PubMed ID: 34697168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombosis in myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of the JAK2 46/1 haplotype with non-splanchnic venous thrombosis.
    Zerjavic K; Zagradisnik B; Lokar L; Krasevac MG; Vokac NK
    Thromb Res; 2013 Aug; 132(2):e86-93. PubMed ID: 23845539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of circulating microparticles in Ph
    Zhang W; Qi J; Zhao S; Shen W; Dai L; Han W; Huang M; Wang Z; Ruan C; Wu D; Han Y
    Oncol Lett; 2017 Aug; 14(2):2531-2536. PubMed ID: 28789461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of erythrocytes and platelets in the hypercoagulable status in polycythemia vera through phosphatidylserine exposure and microparticle generation.
    Tan X; Shi J; Fu Y; Gao C; Yang X; Li J; Wang W; Hou J; Li H; Zhou J
    Thromb Haemost; 2013 Jun; 109(6):1025-32. PubMed ID: 23571603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
    Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
    Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procoagulant microparticles are increased in patients with Behçet's disease but do not define a specific subset of clinical manifestations.
    Mejía JC; Ortiz T; Tàssies D; Solanich X; Vidaller A; Cervera R; Reverter JC; Espinosa G
    Clin Rheumatol; 2016 Mar; 35(3):695-9. PubMed ID: 25711877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splanchnic vein thrombosis in myeloproliferative neoplasms.
    Sekhar M; McVinnie K; Burroughs AK
    Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.